Cargando…

Viral Infection and Lung Cancer Immunotherapy

Immunotherapy with immune checkpoint inhibitors (mainly anti-PD1 and anti-PDL1 monoclonal antibodies) became a standard of care in non-small cell lung cancer (NSCLC) patients. Most of the clinical trials excluded patients with hepatitis B (HBV), hepatis C (HCV), and human immunodeficiency virus (HIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalinka, Ewa, Chmielewska, Izabela, Wojas-Krawczyk, Kamila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381362/ https://www.ncbi.nlm.nih.gov/pubmed/34434887 http://dx.doi.org/10.3389/fonc.2021.577514

Ejemplares similares

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
por: Kalinka, Ewa, et al.
Publicado: (2023)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2020)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
por: Błach, Justyna, et al.
Publicado: (2021)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2021)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Aptamers in Non-Small Cell Lung Cancer Treatment
por: Wieleba, Irena, et al.
Publicado: (2020)

Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases
por: Kubiatowski, Tomasz, et al.
Publicado: (2020)

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2013)

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2022)

Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures
por: Wieleba, Irena, et al.
Publicado: (2022)

Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients
por: Krawczyk, Paweł, et al.
Publicado: (2007)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

The Resistance Mechanisms of Lung Cancer Immunotherapy
por: Wang, Fen, et al.
Publicado: (2020)

Editorial: Impact of immunotherapy in lung cancer
por: Ferreira, Marion, et al.
Publicado: (2022)

The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer
por: Pharaon, Rebecca R., et al.
Publicado: (2021)

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
por: Chmielewska, Izabela, et al.
Publicado: (2023)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

Immunotherapy for Lung Cancer: Has it Finally Arrived?
por: Mostafa, Ahmed A., et al.
Publicado: (2014)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
por: Grenda, Anna, et al.
Publicado: (2022)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
por: Liu, Xiangjun, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy
por: Ocáriz-Díez, Maitane, et al.
Publicado: (2020)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity
por: Bożyk, Aleksandra, et al.
Publicado: (2022)

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
por: Demerlé, Clemence, et al.
Publicado: (2021)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
por: Son, Christine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i5auq5t8e51f00b3toeti5r74a